CHICAGO, IL—In the initial experience following US approval, the Watchman left atrial appendage (LAA) closure device has had a high rate of implant success similar to that seen in the preapproval ...

SAN FRANCISCO — Thirteen months after percutaneous left atrial appendage closure (LAAC), outcomes did not differ whether closure was performed using the Amulet (Abbott Cardiovascular) or the Watchman ...

New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation ...

MARLBOROUGH, Boston Scientific today announced that the first implants of the WATCHMAN FLX ™ Left Atrial Appendage Closure (LAAC) Device – the latest generation of the WATCHMAN Device – occurred in ...

SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure ...

Boston ScientificBSX stock tumbled to a two-year low Monday on mixed test results for its Watchman device in patients at risk of having a stroke. Watchman FLX involves a one-time, minimally invasive ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Rates of patency and device-related thrombus were ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. BOSTON — At 3 years, the Amplatzer Amulet device ...

Cardiology is on the brink of making a big mistake. Our embrace of percutaneous closure of the left atrial appendage as a means of reducing stroke in patients with nonvalvular atrial fibrillation (AF) ...

Medicare typically covers Watchman surgery under Part A (hospital insurance) if deemed medically necessary for reducing stroke risk in patients with non-valvular atrial fibrillation. Coverage often ...